Back To Search Results

Epidemiology Of Study Design

Editor: Sameh W. Boktor Updated: 4/24/2023 12:18:29 PM

Introduction

In epidemiology, researchers are interested in measuring or assessing the relationship between exposure and a disease or an outcome. As a first step, they define the hypothesis based on the research question and then decide which study design is best suited to answer it. How the researcher conducts the investigation is directed by the chosen study design. The study designs can be broadly classified as experimental or observational based on the approach used to assess whether exposure and an outcome are associated. In an experimental study design, researchers assign patients to intervention and control/comparison groups to isolate the effects of the intervention. Being able to control various aspects of the experimental study design enables the researchers to identify causal links between interventions and outcomes of interest. In several instances, an experimental study design may not be feasible or suitable; observational studies are conducted in such situations. As the name indicates, observational studies involve merely observing the patients in a non-controlled environment without actually interfering with or manipulating other aspects of the study and therefore are non-experimental. The observation can be prospective, retrospective, or concurrent, depending on the observational study subtype.[1]

Observational Studies

Case-Control Studies

Case-control studies are used to determine the degree of association between various risk factors and outcomes. The factors that affect disease risk are called exposures. Case-control studies can help identify beneficial or harmful exposures. As the name suggests, a case-control study has 2 groups: cases and controls. Cases are patients who have a particular disease, condition, or disability. Controls are those patients who do not have the disease. Typically, researchers identify appropriate representative controls for the cases that they are studying from the general population. Then they look back in time to identify any exposures these patients might have had to a risk factor. Selecting patients for the control group is a critical component of case-control studies. Due to the retrospective design, case-control studies are subject to recall bias. Case-control studies are inexpensive, efficient, and often less time-consuming to conduct. This study design is particularly well-suited to rare diseases with long latency periods.[2]

Case-Crossover Studies

Case-crossover studies are helpful to study triggers within an individual. When the researcher is studying a transient exposure or risk factor, the case-crossover design is useful. This is a relatively new study design in which a case and a control component come from the same individual. Each case serves as its own control. Determining the periods for the control and case components is a critical yet difficult aspect of a case-crossover study.[3]

Cohort Studies

Cohort studies initially classify patients into 2 groups based on their exposure status. Cohorts are followed over time to see who develops the disease in the exposed and non-exposed groups. Cohort studies can be retrospective or prospective. Incidence can be directly calculated from a cohort study, as you begin with exposed and unexposed patients, unlike a case-control study, where you start with diseased and non-diseased patients. Relative risk is the measure of effect for a cohort study. Cohort studies are subject to very low recall bias, and multiple outcomes can be studied simultaneously. One disadvantage of cohort studies is that they are more prone to selection bias. Studying rare diseases and outcomes with long follow-up periods can be very expensive and time-consuming with cohort studies.[4]

Cross-Sectional Studies

Cross-sectional studies are observational and provide a snapshot of the characteristics of study subjects at a single point in time. Unlike cohort studies, cross-sectional studies lack a follow-up period and are therefore relatively simple to conduct. Because exposure status/outcome-of-interest information is collected at a single point in time, often via surveys, a cross-sectional study design cannot establish a cause-and-effect relationship and is the weakest observational design. This study design is generally used to assess the prevalence of a disease in a population.[5]

Ecological Studies

Ecological studies are used when individual-level data are unavailable or when large-scale comparisons are needed to study the population-level effects of exposures on a disease condition. Therefore, ecological study results are applicable only at the population level. The types of measures in ecological studies are aggregates of individual-level data. These studies, therefore, are subject to a type of confounding called the ecological fallacy, which occurs when relationships identified at the group level are assumed to hold for individuals. Ecological studies are generally used in public health research.[6]

Experimental Studies

Randomized Clinical Trials

Randomized clinical trials or randomized controlled trials (RCTs) are considered the gold standard of study design. In an RCT, the researcher randomly assigns the subjects to a control group and an experimental group. Randomization in RCT avoids confounding and minimizes selection bias. This enables the researcher to have similar experimental and control groups, thereby enabling them to isolate the effect of an intervention. The experimental group gets the exposure/treatment, which can be an agent involved in the causation, prevention, or treatment of a disease. The control group receives no treatment, a placebo, or another standard-of-care treatment, depending on the study's objective. The groups are then followed prospectively to see who develops the outcome of interest. RCTs are expensive, and researchers using this study design often face issues with randomization integrity due to refusals, dropouts, crossovers, and non-compliance.[7][8]

Function

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Function

The key function of an epidemiology study design is to enable the researcher to address the research question logically with minimal ambiguity.

Issues of Concern

Study design should be well thought out before initiating a research investigation. Choosing an inappropriate study design may undermine the overall validity of the study. Critical thinking about potential study design issues in advance ensures that the research question is adequately addressed.

Clinical Significance

Study design plays a major role in determining the scientific value of a research study. Understanding the basic study design concepts aids clinicians in practicing evidence-based medicine.[9]

Other Issues

Errors in study design are extremely difficult to correct after study completion. Thorough planning is required to avoid weak conclusions or unconvincing results.

Enhancing Healthcare Team Outcomes

All interprofessional healthcare team members, including clinicians, mid-level practitioners, nurses, pharmacists, and therapists, need to be well-versed in the study designs used in medical research. Such knowledge can help distinguish strong studies and results from weaker ones, assess the clinical applicability of study findings, and enhance patient care through the appropriate application of data-driven research. Failure to understand study design and the strengths of data from various study types can lead to improper decision-making and negatively impact patient outcomes.[10]

References


[1]

Chatburn RL. Basics of study design: Practical considerations (From the "Biostatistics and Epidemiology Lecture Series, Part 1"). Cleveland Clinic journal of medicine. 2017 Sep:84(9 Suppl 2):e10-e19. doi: 10.3949/ccjm.84.s2.03. Epub     [PubMed PMID: 28937358]


[2]

Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes research and clinical practice. 2010 May:88 Suppl 1():S3-9. doi: 10.1016/S0168-8227(10)70002-4. Epub     [PubMed PMID: 20466165]

Level 1 (high-level) evidence

[3]

Röhrig B, du Prel JB, Wachtlin D, Blettner M. Types of study in medical research: part 3 of a series on evaluation of scientific publications. Deutsches Arzteblatt international. 2009 Apr:106(15):262-8. doi: 10.3238/arztebl.2009.0262. Epub 2009 Apr 10     [PubMed PMID: 19547627]


[4]

DiPietro NA. Methods in epidemiology: observational study designs. Pharmacotherapy. 2010 Oct:30(10):973-84. doi: 10.1592/phco.30.10.973. Epub     [PubMed PMID: 20874034]

Level 2 (mid-level) evidence

[5]

Noordzij M, Dekker FW, Zoccali C, Jager KJ. Study designs in clinical research. Nephron. Clinical practice. 2009:113(3):c218-21. doi: 10.1159/000235610. Epub 2009 Aug 18     [PubMed PMID: 19690439]

Level 2 (mid-level) evidence

[6]

Buckley HL, Day NJ, Lear G, Case BS. Changes in the analysis of temporal community dynamics data: a 29-year literature review. PeerJ. 2021:9():e11250. doi: 10.7717/peerj.11250. Epub 2021 Apr 8     [PubMed PMID: 33889452]

Level 3 (low-level) evidence

[7]

Hiebert R, Nordin M. Methodological aspects of outcomes research. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2006 Jan:15 Suppl 1(Suppl 1):S4-16     [PubMed PMID: 16317562]

Level 2 (mid-level) evidence

[8]

Lilli C, Biggeri A, Zingaretti C, Vertogen B, Frassineti V, Vespignani R, Grossi V, Florescu C, Matteucci L, Pazzi C, Bongiovanni A, Limarzi F, Fausti V, Bertoni L, Donati C, Galardi F, Gentili N, Mazza F, Martinelli G, Nanni O. Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. Epidemiologia e prevenzione. 2021 Jan-Apr:45(1-2):28-36. doi: 10.19191/EP21.1-2.P028.036. Epub     [PubMed PMID: 33884840]


[9]

Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO open. 2021 Jun:6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20     [PubMed PMID: 33887690]


[10]

Mahendraratnam N, Mercon K, Gill M, Benzing L, McClellan MB. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness. Clinical pharmacology and therapeutics. 2022 Jan:111(1):150-154. doi: 10.1002/cpt.2272. Epub 2021 Jul 2     [PubMed PMID: 33891318]

Level 3 (low-level) evidence